Pazopanib with topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase i/ii study (topaz)

HIGHLIGHTS

• who: Radoslav Chekerov from the Patients and methods Study design and objectives TOPAZ was a multicentre, single arm, prospective, phase I/II study, performed by academic researchers of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) ovarian cancer study groupThe phase-I part was conducted within a, month recruitment period (increased with , months in the first protocol amendment on December, and with , months by the second protocol amendment on Mai, ) at two German gynaecological oncology centres-the Charitu00e9 University Hospital Berlin and the University Hospital Leipzig. In the phase II conducted within a recruitment period of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.